Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat study: Acta Ophthalmologica

M Fallico; T Avitabile; N Castellino; A Longo; A Russo; V Bonfiglio; F Parisi; C Furino; G Panozzo; V Scorcia; A Carnevali; F Bandello; M Battaglia Parodi; G Cennamo; S Cillino; M Vadalà; V Sunseri Trapani; C Cagini; T Fiore; M Lupidi; M Parravano; M Varano; P Giorno; F Boscia; E Giancipoli; C Eandi; Y Le Mer; M Reibaldi

doi:10.1111/aos.14516

Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat study: Acta Ophthalmologica

M Fallico, T Avitabile, N Castellino, A Longo, A Russo, V Bonfiglio, F Parisi, C Furino, G Panozzo, V Scorcia, A Carnevali, F Bandello, M Battaglia Parodi, G Cennamo, S Cillino, M Vadalà, V Sunseri Trapani, C Cagini, T Fiore, M LupidiM Parravano, M Varano, P Giorno, F Boscia, E Giancipoli, C Eandi, Y Le Mer, M Reibaldi

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose: To report clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery. Methods: This multicentre, retrospective study included patients with DME who received an intravitreal DEX implant 1 month before cataract surgery, ‘precataract DEX’ group, or at the time of cataract surgery, ‘concomitant treatments’ group. Inclusion criteria were a follow-up ≥3 months and ophthalmological examination with optical coherence tomography (OCT) imaging at baseline (cataract surgery) and throughout follow-up. Anatomical improvement was considered to be a decrease in OCT central subfield (CSF) thickness ≥20% compared to baseline. The primary outcomes were anatomical and functional results at 3 months. Results: Two hundred twenty-one patients were included: 136 in the ‘precataract DEX’ group and 85 in the ‘concomitant treatments’ group. At 3 months, a reduction of CSF thickness ≥ 20% was found in 7.3% of eyes in the ‘precataract DEX group’ and in 83.7% of eyes in the ‘concomitant treatments’ group (p

Original language	English
Pages (from-to)	e74-e80
Journal	Acta Ophthalmologica
Volume	99
Issue number	1
DOIs	https://doi.org/10.1111/aos.14516
Publication status	Published - 2021

Access to Document

10.1111/aos.14516

Cite this

Fallico, M., Avitabile, T., Castellino, N., Longo, A., Russo, A., Bonfiglio, V., Parisi, F., Furino, C., Panozzo, G., Scorcia, V., Carnevali, A., Bandello, F., Battaglia Parodi, M., Cennamo, G., Cillino, S., Vadalà, M., Sunseri Trapani, V., Cagini, C., Fiore, T., ... Reibaldi, M. (2021). Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat study: Acta Ophthalmologica. Acta Ophthalmologica, 99(1), e74-e80. https://doi.org/10.1111/aos.14516

Fallico, M, Avitabile, T, Castellino, N, Longo, A, Russo, A, Bonfiglio, V, Parisi, F, Furino, C, Panozzo, G, Scorcia, V, Carnevali, A, Bandello, F , Battaglia Parodi, M, Cennamo, G, Cillino, S, Vadalà, M, Sunseri Trapani, V, Cagini, C, Fiore, T, Lupidi, M, Parravano, M , Varano, M , Giorno, P, Boscia, F, Giancipoli, E, Eandi, C, Le Mer, Y & Reibaldi, M 2021, 'Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat study: Acta Ophthalmologica', Acta Ophthalmologica, vol. 99, no. 1, pp. e74-e80. https://doi.org/10.1111/aos.14516

@article{59296113686f45ba88a5d1b95d1d1425,

title = "Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat study: Acta Ophthalmologica",

abstract = "Purpose: To report clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery. Methods: This multicentre, retrospective study included patients with DME who received an intravitreal DEX implant 1 month before cataract surgery, {\textquoteleft}precataract DEX{\textquoteright} group, or at the time of cataract surgery, {\textquoteleft}concomitant treatments{\textquoteright} group. Inclusion criteria were a follow-up ≥3 months and ophthalmological examination with optical coherence tomography (OCT) imaging at baseline (cataract surgery) and throughout follow-up. Anatomical improvement was considered to be a decrease in OCT central subfield (CSF) thickness ≥20% compared to baseline. The primary outcomes were anatomical and functional results at 3 months. Results: Two hundred twenty-one patients were included: 136 in the {\textquoteleft}precataract DEX{\textquoteright} group and 85 in the {\textquoteleft}concomitant treatments{\textquoteright} group. At 3 months, a reduction of CSF thickness ≥ 20% was found in 7.3% of eyes in the {\textquoteleft}precataract DEX group{\textquoteright} and in 83.7% of eyes in the {\textquoteleft}concomitant treatments{\textquoteright} group (p ",

author = "M Fallico and T Avitabile and N Castellino and A Longo and A Russo and V Bonfiglio and F Parisi and C Furino and G Panozzo and V Scorcia and A Carnevali and F Bandello and {Battaglia Parodi}, M and G Cennamo and S Cillino and M Vadal{\`a} and {Sunseri Trapani}, V and C Cagini and T Fiore and M Lupidi and M Parravano and M Varano and P Giorno and F Boscia and E Giancipoli and C Eandi and {Le Mer}, Y and M Reibaldi",

year = "2021",

doi = "10.1111/aos.14516",

language = "English",

volume = "99",

pages = "e74--e80",

journal = "Acta Ophthalmologica",

issn = "1755-375X",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "1",

}

TY - JOUR

T1 - Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat study

T2 - Acta Ophthalmologica

AU - Fallico, M

AU - Avitabile, T

AU - Castellino, N

AU - Longo, A

AU - Russo, A

AU - Bonfiglio, V

AU - Parisi, F

AU - Furino, C

AU - Panozzo, G

AU - Scorcia, V

AU - Carnevali, A

AU - Bandello, F

AU - Battaglia Parodi, M

AU - Cennamo, G

AU - Cillino, S

AU - Vadalà, M

AU - Sunseri Trapani, V

AU - Cagini, C

AU - Fiore, T

AU - Lupidi, M

AU - Parravano, M

AU - Varano, M

AU - Giorno, P

AU - Boscia, F

AU - Giancipoli, E

AU - Eandi, C

AU - Le Mer, Y

AU - Reibaldi, M

PY - 2021

Y1 - 2021

N2 - Purpose: To report clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery. Methods: This multicentre, retrospective study included patients with DME who received an intravitreal DEX implant 1 month before cataract surgery, ‘precataract DEX’ group, or at the time of cataract surgery, ‘concomitant treatments’ group. Inclusion criteria were a follow-up ≥3 months and ophthalmological examination with optical coherence tomography (OCT) imaging at baseline (cataract surgery) and throughout follow-up. Anatomical improvement was considered to be a decrease in OCT central subfield (CSF) thickness ≥20% compared to baseline. The primary outcomes were anatomical and functional results at 3 months. Results: Two hundred twenty-one patients were included: 136 in the ‘precataract DEX’ group and 85 in the ‘concomitant treatments’ group. At 3 months, a reduction of CSF thickness ≥ 20% was found in 7.3% of eyes in the ‘precataract DEX group’ and in 83.7% of eyes in the ‘concomitant treatments’ group (p

AB - Purpose: To report clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery. Methods: This multicentre, retrospective study included patients with DME who received an intravitreal DEX implant 1 month before cataract surgery, ‘precataract DEX’ group, or at the time of cataract surgery, ‘concomitant treatments’ group. Inclusion criteria were a follow-up ≥3 months and ophthalmological examination with optical coherence tomography (OCT) imaging at baseline (cataract surgery) and throughout follow-up. Anatomical improvement was considered to be a decrease in OCT central subfield (CSF) thickness ≥20% compared to baseline. The primary outcomes were anatomical and functional results at 3 months. Results: Two hundred twenty-one patients were included: 136 in the ‘precataract DEX’ group and 85 in the ‘concomitant treatments’ group. At 3 months, a reduction of CSF thickness ≥ 20% was found in 7.3% of eyes in the ‘precataract DEX group’ and in 83.7% of eyes in the ‘concomitant treatments’ group (p

U2 - 10.1111/aos.14516

DO - 10.1111/aos.14516

M3 - Article

SN - 1755-375X

VL - 99

SP - e74-e80

JO - Acta Ophthalmologica

JF - Acta Ophthalmologica

IS - 1

ER -

Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat study: Acta Ophthalmologica

Abstract

Access to Document

Fingerprint

Cite this